Daiichi Sankyo Rolls Out Generics In Japan While Ranbaxy Products Still On Hold In U.S.

Related Content

Asia Spotlight: Ranbaxy CEO Arun Sawhney On “Thrilling” Days Of Atorvastatin Approvals And What’s Next

Ranbaxy CEO Arun Sawhney On What’s Next After Lipitor – An Exclusive PharmAsia News Interview (Part 2 of 2)

India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle

India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle

Kyorin Rejects Sawai's Merger Proprosal, Leaving Japan's Generics Leader Scrambling Ahead Of Big Pharma Competition

Daiichi Sankyo To Revamp Prasugrel's U.S. Marketing After Sluggish Sales

Ranbaxy May Be Hit With Significant Disgorgement Penalty For GMP Violations

Ranbaxy Outperforms Behind Generic Valtrex, But FDA Corrective Action Looms

Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy

Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy